As of 2025-09-17, the Intrinsic Value of Akero Therapeutics Inc (AKRO) is -17.75 USD. This AKRO valuation is based on the model Peter Lynch Fair Value. With the current market price of 42.60 USD, the upside of Akero Therapeutics Inc is -141.67%.
Based on its market price of 42.60 USD and our intrinsic valuation, Akero Therapeutics Inc (AKRO) is overvalued by 141.67%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -17.75 - -17.75 | -17.75 | -141.67% |
| P/E | (49.06) - (61.13) | (49.34) | -215.8% |
| DDM - Stable | (32.91) - (111.55) | (72.23) | -269.5% |
| DDM - Multi | (0.47) - (1.20) | (0.67) | -101.6% |
| Market Cap (mil) | 3,407.57 |
| Beta | 0.61 |
| Outstanding shares (mil) | 79.99 |
| Enterprise Value (mil) | 3,222.79 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.21% |
| Cost of Debt | 5.00% |
| WACC | 9.15% |